Teva Pharmaceutical Industries Limited (NYSE:TEVA) was downgraded by analysts at Cowen and Company from an “outperform” rating to a “market perform” rating in a report released on Friday, Marketbeat.com reports. They presently have a $30.00 target price on the stock. Cowen and Company’s price objective would suggest a potential upside of 45.63% from the stock’s current price.

A number of other equities research analysts have also issued reports on TEVA. Royal Bank Of Canada lowered shares of Teva Pharmaceutical Industries Limited from an “outperform” rating to an “underperform” rating and dropped their price objective for the company from $37.00 to $21.00 in a report on Friday. Credit Suisse Group lowered shares of Teva Pharmaceutical Industries Limited from an “outperform” rating to a “neutral” rating in a report on Friday. Maxim Group reaffirmed a “hold” rating and issued a $35.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, July 13th. Jefferies Group LLC reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, July 25th. Finally, Mizuho reaffirmed a “hold” rating and issued a $30.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday. One research analyst has rated the stock with a sell rating, twenty-two have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $39.81.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down 13.26% during midday trading on Friday, hitting $20.60. 93,317,085 shares of the stock traded hands. The stock has a 50-day moving average of $32.05 and a 200 day moving average of $32.28. The firm has a market cap of $20.93 billion, a PE ratio of 264.10 and a beta of 0.46. Teva Pharmaceutical Industries Limited has a 52-week low of $20.41 and a 52-week high of $55.45. Teva Pharmaceutical Industries Limited also was the recipient of some unusual options trading activity on Thursday. Investors purchased 66,716 put options on the company. This is an increase of approximately 864% compared to the average daily volume of 6,922 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.18%. The firm had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. During the same period in the prior year, the company posted $1.25 EPS. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post $4.65 EPS for the current year.

WARNING: “Teva Pharmaceutical Industries Limited (NYSE:TEVA) Cut to Market Perform at Cowen and Company” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/06/teva-pharmaceutical-industries-limited-nyseteva-cut-to-market-perform-at-cowen-and-company.html.

A number of hedge funds have recently modified their holdings of TEVA. Sii Investments Inc. WI raised its position in shares of Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Sii Investments Inc. WI now owns 6,739 shares of the company’s stock valued at $214,000 after buying an additional 25 shares in the last quarter. Salem Investment Counselors Inc. raised its position in shares of Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Salem Investment Counselors Inc. now owns 8,332 shares of the company’s stock valued at $267,000 after buying an additional 32 shares in the last quarter. Cribstone Capital Management LLC raised its position in shares of Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock valued at $101,000 after buying an additional 100 shares in the last quarter. Financial Architects Inc raised its position in shares of Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock valued at $143,000 after buying an additional 100 shares in the last quarter. Finally, Sterling Investment Advisors Ltd. raised its position in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares in the last quarter. 56.20% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.